文献速递银屑病与炎症性皮肤病

银屑病患者使用Cal/BD泡沫主动或被动管理的生活质量与症状:PSO-LONG事后分析

Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-10-21

开放标签4周后随机维持52周,结果显示所有PRO显著改善,主动管理组DLQI和PSI显著优于被动管理组。

要点

  • Cal/BD泡沫治疗4周显著改善PSI、DLQI和EQ-5D-5L-PSO评分。
  • 维持期主动管理组DLQI和PSI显著优于被动管理组。
  • 基线发作期患者PRO较复发起始或缓解期更差。

核心结论

  • Cal/BD泡沫在开放标签和维持期显著改善DLQI、EQ-5D-5L-PSO和PSI评分。
  • 主动管理组DLQI和PSI显著优于被动管理组,EQ-5D-5L-PSO数值更优但未达统计学显著。
  • 基线发作期患者PRO较复发起始或缓解期更差。

研究设计与样本

  • 3期随机双盲试验,先4周开放标签Cal/BD泡沫每日一次,再52周维持期随机分为主动管理(每周两次Cal/BD泡沫)或被动管理(每周两次赋形剂泡沫)。

主要发现

  • 从基线到第4周,PSI平均差异(标准差)为-8.97(6.18),DLQI为-6.02(5.46),EQ-5D-5L-PSO为0.11(0.15)。
  • 维持期被动管理组DLQI较主动管理组高15%(p=0.007),PSI高15%(p=0.0128)。
  • 维持期被动管理组EQ-5D-5L-PSO平均AUC评分较主动管理组数值低1%(p=0.0842)。

临床怎么用

  • 对于银屑病 vulgaris 患者,可考虑使用Cal/BD泡沫进行主动管理以改善生活质量和患者感知症状。
  • 治疗初期4周每日一次Cal/BD泡沫可显著改善PRO,维持期每周两次主动管理优于被动管理。

局限性

  • 为事后分析,结果需谨慎解释。
  • EQ-5D-5L-PSO差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis has important physical and psychosocial effects that extend beyond the skin. Understanding the impact of treatment on health-related quality of life (HRQoL) and patient-perceived symptom severity in psoriasis is key to clinical decision-making. OBJECTIVES: This post hoc analysis of the PSO-LONG trial data assessed the impact of long-term proactive or reactive management with fixed-dose combination calcipotriene 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam on patient-reported outcomes (PROs) in patients with psoriasis vulgaris. METHODS: Five hundred and twenty-one patients from the Phase 3, randomized, double-blind PSO-LONG trial were included. An initial 4-week, open-label phase of fixed-dose combination Cal/BD foam once daily (QD) was followed by a 52-week maintenance phase, at the start of which patients were randomized to a proactive management arm (Cal/BD foam twice weekly) or reactive management arm (vehicle foam twice weekly). Patient-perceived symptom severity and HRQoL were assessed using the Psoriasis Symptom Inventory (PSI), the Dermatology Life Quality Index (DLQI) and the EuroQol-5D for psoriasis (EQ-5D-5L-PSO). RESULTS: Statistically and clinically significant improvements were observed across all PRO measures. The mean difference (standard deviation) from baseline to Week 4 was -8.97 (6.18) for PSI, -6.02 (5.46) for DLQI and 0.11 (0.15) for EQ-5D-5L-PSO scores. During maintenance, patients receiving reactive management had significantly higher DLQI (15% [p = 0.007]) and PSI (15% [p = 0.0128]) and a numerically lower EQ-5D-5L-PSO mean area under the curve score than patients receiving proactive management (1% [p = 0.0842]). CONCLUSIONS: Cal/BD foam significantly improved DLQI, EQ-5D-5L-PSO and PSI scores during the open-label and maintenance phases. Patients assigned to proactive management had significantly better DLQI and PSI scores and numerically better EQ-5D-5L-PSO versus reactive management. Additionally, baseline flare was associated with worse PROs than the start of a relapse, and patients starting a relapse also had worse PROs than patients in remission.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Jalili A, Calzavara-Pinton P, Kircik L, et al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG. J Eur Acad Dermatol Venereol. 2021. PMID: 34543474. doi:10.1111/jdv.17673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。